Lomardexamfetamine

Lomardexamfetamine (INNTooltip International Nonproprietary Name; developmental code name KP-106), also known as L-homoarginine-D-amphetamine, is a psychostimulant of the amphetamine family which was under development for the treatment of attention deficit hyperactivity disorder (ADHD) but was never marketed.^[1][2][3] It is taken orally as an oral film.^[1] The drug is a prodrug of dextroamphetamine analogously to lisdexamfetamine and with similarly reduced misuse potential.^[3][4] Lomardexamfetamine was originated and under development by KemPharm (now known as Zevra Therapeutics).^[1][2][3] It reached phase 1 clinical trials prior to the discontinuation of its development in 2013.^[1][2][3]

Other namesKP106; L-Homoarginine-D-amphetamine

Routes of
administrationOral^[1]

Drug classNorepinephrine–dopamine releasing agent; Stimulant

ATC code

• None

Quick facts Clinical data, Other names ...

Lomardexamfetamine

Clinical data
Other names	KP106; L-Homoarginine-D-amphetamine
Routes of administration	Oral[1]
Drug class	Norepinephrine–dopamine releasing agent; Stimulant
ATC code	None
Identifiers
IUPAC name (2S)-2-amino-6-(diaminomethylideneamino)-N-[(2S)-1-phenylpropan-2-yl]hexanamide
CAS Number	1032291-80-7
PubChem CID	44201340
DrugBank	DB21459
ChemSpider	81368305
UNII	Q5L4P8K8QZ
Chemical and physical data
Formula	C16H27N5O
Molar mass	305.426 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN=C(N)N)N
InChI InChI=1S/C16H27N5O/c1-12(11-13-7-3-2-4-8-13)21-15(22)14(17)9-5-6-10-20-16(18)19/h2-4,7-8,12,14H,5-6,9-11,17H2,1H3,(H,21,22)(H4,18,19,20)/t12-,14-/m0/s1 Key:DRLPEFJOKVYESM-JSGCOSHPSA-N

Close